Articles dans des revues avec comité de lecture (167)
  1. 80. Vereecken, P., Zouaoui Boudjeltia, K., Debray, C., Awada, A., Legssyer, I., Sales, F., Petein, M., Vanhaeverbeek, M., Ghanem, G. E., & Heenen, M. (2006). High serum galectin-3 in advanced melanoma: preliminary results. Clinical and experimental dermatology, 31(1), 105-109. doi:10.1111/j.1365-2230.2005.01992.x
  2. 81. Kinnaert, E., Duez, P., Morandini, R., Dubois, J., Van Houtte, P., & Ghanem, G. E. (2004). Cysteine but not glutathione modulates the radiosensitivity of human melanoma cells by affecting both survival and DNA damage. Pigment cell research, 17(3), 275-280. doi:10.1111/j.1600-0749.2004.00146.x
  3. 82. Lugassy, C., Kleinman, H. K., Engbring, J. A., Welch, D. R., Harms, J. F., Rufner, R., Ghanem, G. E., Patierno, S. R., & Barnhill, R. L. (2004). Pericyte-like location of GFP-tagged melanoma cells: ex vivo and in vivo studies of extravascular migratory metastasis. The American journal of pathology, 164(4), 1191-1198.
  4. 83. Dierickx, K. M. E., Morandini, R., & Ghanem, G. E. (2004). Study of l-prolyl-m-l-sarcolysyl-l-p fluorophenylalanineethylesther (PSF) a new anticancer drug candidate and its mechanism of action. Acta clinica Belgica (Ed. multilingue), 59(2), 109-122.
  5. 84. Stoitchkov, K., Letellier, S., Garnier, J.-P., Bousquet, B., Tsankov, N., Morel, P., Ghanem, G. E., & Le Bricon, T. (2003). Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma research, 13(6), 587-593. doi:10.1097/01.cmr.0000056284.15046.b6
  6. 85. Eves, P., Haycock, J. W., Layton, C., Wagner, M., Kemp, H., Szabo, M., Morandini, R., Ghanem, G. E., García-Borrón, J. C., Jimenez-Cervantes Frigo, C., & Mac Neil, S. (2003). Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. British Journal of Cancer, 89(10), 2004-2015. doi:10.1038/sj.bjc.6601349
  7. 86. Morandini, R., Nguyen, T. H., & Ghanem, G. E. (2003). L-prolyl-m-L-Sarcolysyl-L-p-Flurophenylalanine ethylesther, HCl (PSF) evaluation in human melanoma-bearing nude mice. Acta clinica Belgica (Ed. multilingue), 58(2), 126-147.
  8. 87. Moustafa, M., Szabo, M., Ghanem, G. E., Morandini, R., Kemp, E. H., MacNeil, S., & Haycock, J. W. (2002). Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. Journal of investigative dermatology, 119(6), 1244-1253. doi:10.1046/j.1523-1747.2002.19602.x
  9. 88. Sánchez Más, J., Olivares Sánchez, C., Ghanem, G. E., Haycock, J. W., Lozano Teruel, J. A., García-Borrón, J. C., & Jimenez-Cervantes Frigo, C. (2002). Loss-of-function variants of the human melanocortin-1 receptor gene in melanoma cells define structural determinants of receptor function. European journal of biochemistry / FEBS, 269(24), 6133-6141. doi:10.1046/j.1432-1033.2002.03329.x
  10. 89. Brouard, M. C., Saurat, J. H., Ghanem, G. E., & Siegenthaler, G. (2002). Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma. Melanoma research, 12(6), 627-631. doi:10.1097/01.cmr.0000043147.28051.f1
  11. 90. Zhu, N., Eves, P. C., Katerinaki, E., Szabo, M., Morandini, R., Ghanem, G. E., Lorigan, P., MacNeil, S., & Haycock, J. W. (2002). Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. Journal of investigative dermatology, 119(5), 1165-1171. doi:10.1046/j.1523-1747.2002.19516.x
  12. 91. Lugassy, C., Kleinman, H. K., Fernandez, P. M., Patierno, S. R., Webber, M. M., Ghanem, G. E., Spatz, A., & Barnhill, R. L. (2002). Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis. Journal of investigative dermatology, 119(3), 703-704. doi:10.1046/j.1523-1747.2002.01857.x
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Suivant >>